Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, have been published in Clinical Genitourinary Cancer.
The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.
Discover more about how we help to shape the future of oncology treatments here.
Jump to a slide with the slide dots.
Inizio Medical’s MSL Interact, powered by iON.AI, Named Innovation of the Year at the British Data Awards 2025
Inizio Medical & Blend win Innovation of the Year at the 2025 British Data Awards for MSL Interact, a breakthrough in AI-driven HCP training.
Read moreReimagining the future of oncology, together
We’re delighted to be on the ground at the 2025 ASCO® Annual Meeting as the trusted partner for health and life sciences organizations navigating...
Read moreStephanie Tortell Announced as Candidate for ISMPP Chair-Elect 2025
At Inizio, we are proud to support leaders who exemplify excellence, integrity, and a deep commitment to advancing healthcare communications.
Read more